Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable
International Clinical Psychopharmacology, 08/17/2012
Duncan EJ et al. – Metabolic monitoring frequency was significantly greater for patients switched to Risperidone in long–acting injectable form (RLAI) for patients maintained on oral risperidone (RispPO) treatment. Outpatient medication compliance is enhanced during treatment with RLAI compared with treatment with RispPO, as is the rate of monitoring for metabolic measures.Methods
- The authors carried out a retrospective study using a computerized repository of clinical data from eight Veterans Affairs Medical Centers.
- Compliance with outpatient medication and metabolic monitoring frequency was evaluated in schizophrenia spectrum patients during treatment with oral risperidone (RispPO) and after switch to RLAI.
- Propensity scores were computed during baseline when both groups were on RispPO, and the two groups were matched on propensity scores.
- Matching on propensity score was successful: 132 RispPO patients were well matchedto 132 RLAI patients during the RispPO Baseline Period.
- Days until medication discontinuation were longer in the RLAI group (679.2±499.3) than the RispPO group (403.7±365.1, P<0.0001).
- Days late for receiving medication were significantly shorter during the RLAI treatment (5.6±6.2) than the RispPO treatment (8.2±8.6, P<0.004).
- Metabolic monitoring frequency was significantly greater for patients switched to RLAI for patients maintained on RispPO treatment.